Fingerprint
Dive into the research topics of 'Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
Abhishek Maiti, Kiran Naqvi, Tapan M. Kadia, Gautam Borthakur, Koichi Takahashi, Prithviraj Bose, Naval G. Daver, Ami Patel, Yesid Alvarado, Maro Ohanian, Courtney D. DiNardo, Jorge E. Cortes, Elias J. Jabbour, Guillermo Garcia-Manero, Hagop M. Kantarjian, Farhad Ravandi
Research output: Contribution to journal › Article › peer-review
35
Scopus
citations